ZYDUS LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,053 INR | -0.52% |
|
-3.25% | +52.78% |
| Sales 2024 | 195B 2.35B | Sales 2025 * | 217B 2.61B | Capitalization | 1,060B 12.74B |
|---|---|---|---|---|---|
| Net income 2024 | 38.6B 464M | Net income 2025 * | 42.66B 513M | EV / Sales 2024 | 5.19 x |
| Net cash position 2024 * | 13.47B 162M | Net cash position 2025 * | 29.52B 355M | EV / Sales 2025 * | 4.74 x |
| P/E ratio 2024 |
26.4
x | P/E ratio 2025 * |
25.3
x | Employees | 23,026 |
| Yield 2024 * |
0.55% | Yield 2025 * |
0.51% | Free-Float | 24.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zydus Lifesciences Limited
More recommendations
More press releases
| 1 day | -0.52% | ||
| 1 week | -3.25% | ||
| Current month | +10.42% | ||
| 1 month | +11.14% | ||
| 3 months | +12.90% | ||
| 6 months | +67.19% | ||
| Current year | +52.78% |
1 week
1 040.40
1 105.00
1 month
948.951 172.50
Current year
686.001 172.50
1 year
498.851 172.50
3 years
319.001 172.50
5 years
202.001 172.50
10 years
182.221 172.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 97-07-31 | |
| Director of Finance/CFO | - | - | |
| Chairman | 71 | 95-05-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 18-12-05 | |
| Chairman | 71 | 95-05-14 | |
| Director/Board Member | 69 | 97-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 6 M€ | +6.07% | - | |
| 0.01% | 112 M€ | +4.44% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 1,053 | -0.52% | 1,516,739 |
| 24-05-27 | 1,058 | -1.63% | 1,812,394 |
| 24-05-24 | 1,076 | -0.93% | 2,735,393 |
| 24-05-23 | 1,086 | +0.50% | 2,041,787 |
| 24-05-22 | 1,081 | -0.71% | 2,865,788 |
Delayed Quote NSE India S.E., May 28, 2024 at 07:43 am EDT
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
30
Last Close Price
1,053
INR
Average target price
992.1
INR
Spread / Average Target
-5.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.78% | 12.81B | |
| +16.31% | 42.32B | |
| +15.77% | 21.29B | |
| +19.33% | 15.29B | |
| +18.71% | 14.36B | |
| -0.05% | 6.79B | |
| -12.34% | 6.58B | |
| -8.87% | 5.73B | |
| +14.28% | 5.51B | |
| +7.31% | 4.91B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
